China IPO Roundup: Strong Spring Financings For Pharma And Biotech

08 May 2017

• By Ying Huang

China’s healthcare sector was back to actively raising proceeds from the capital markets in March and April, which witnessed more than 20 IPOs in total, with a stream of other listings being planned.

Share sales in the pharmaceutical and life science sector in China have been rebounding since March, driven by a string of listings in mainland China and the first initial public offering by a Chinese company this year on Nasdaq in the US.

On March 9, cancer therapeutics bioventure BeyondSpring Inc. raised $54.3m in a combination of an IPO and private placement...